Finance

Lists
STAR:NSE
Strides Pharma Science Ltd
978,10 INR
-0,81%
(-8,00) 1D
17 ნოე, 15:30:02 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
980,50 INR
High
1 000,00 INR
Low
973,00 INR
Mkt. cap
90,16 მლრდ.
Avg. vol.
354,46 ათ.
Volume
238,82 ათ.
Dividend
0,51%
Quarterly dividend
1,25 INR
Ex-dividend date
31 ივლ. 2026
P/E ratio
14,62
52-wk high
1 260,90 INR
52-wk low
768,65 INR
EPS
66,90 INR
Shares outstanding
89,55 მლნ.
No. of employees
4 ათ.
Open
980,50 INR
High
1 000,00 INR
Low
973,00 INR
Mkt. cap
90,16 მლრდ.
Avg. vol.
354,46 ათ.
Volume
238,82 ათ.
Dividend
0,51%
Quarterly dividend
1,25 INR
Ex-dividend date
31 ივლ. 2026
P/E ratio
14,62
52-wk high
1 260,90 INR
52-wk low
768,65 INR
EPS
66,90 INR
Shares outstanding
89,55 მლნ.
No. of employees
4 ათ.
News stories
From web sources and news partners
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3,54 ათ.
Founded1990
Headquartersბენგალურუ, კარნატაკა, ინდოეთი
SectorHealth Care
IndustryPharmaceutical industry
Last report
30 ოქტ. 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
14,30 მლრდ. / 14,15 მლრდ.
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
11,95 მლრდ.
13,23 მლრდ.
12,65 მლრდ.
14,30 მლრდ.
Cost of goods sold
4,63 მლრდ.
7,19 მლრდ.
4,95 მლრდ.
6,29 მლრდ.
Cost of revenue
4,63 მლრდ.
7,19 მლრდ.
4,95 მლრდ.
6,29 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,30 მლრდ.
3,45 მლრდ.
2,43 მლრდ.
2,38 მლრდ.
Operating expense
5,46 მლრდ.
4,91 მლრდ.
5,97 მლრდ.
6,07 მლრდ.
Total operating expenses
10,09 მლრდ.
12,10 მლრდ.
10,92 მლრდ.
12,36 მლრდ.
Operating income
1,85 მლრდ.
1,13 მლრდ.
1,73 მლრდ.
1,94 მლრდ.
Other non operating income
1,07 მლრდ.
-1,66 მლრდ.
48,90 მლნ.
40,83 მლნ.
EBT including unusual items
2,45 მლრდ.
1,48 მლრდ.
2,00 მლრდ.
1,50 მლრდ.
EBT excluding unusual items
2,49 მლრდ.
502,07 მლნ.
1,36 მლრდ.
1,52 მლრდ.
Income tax expense
373,53 მლნ.
187,70 მლნ.
341,23 მლნ.
163,18 მლნ.
Effective tax rate
15,22%
12,68%
17,09%
10,85%
Other operating expenses
2,66 მლრდ.
928,53 მლნ.
2,97 მლრდ.
3,11 მლრდ.
Net income
2,02 მლრდ.
1,27 მლრდ.
1,57 მლრდ.
1,31 მლრდ.
Net profit margin
16,92%
9,59%
12,40%
9,15%
Earnings per share
-
-
-
-
Interest and investment income
-
404,82 მლნ.
-
-
Interest expense
-433,79 მლნ.
-130,82 მლნ.
-405,61 მლნ.
-465,41 მლნ.
Net interest expenses
-433,79 მლნ.
274,00 მლნ.
-405,61 მლნ.
-465,41 მლნ.
Depreciation and amortization charges
506,23 მლნ.
532,49 მლნ.
563,99 მლნ.
572,15 მლნ.
EBITDA
2,25 მლრდ.
1,55 მლრდ.
2,15 მლრდ.
2,51 მლრდ.
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google აპები